Exploring Ritlecitinib for Alopecia Areata

Opinion Video Author(s): Panelists discuss how ritlecitinib, approved by the FDA in 2023 as the first Janus kinase (JAK) inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and integration into the AA treatment algorithm, while addressing concerns around drug-to-drug interactions. Video content above is prompted by the following: Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. A Population Health Approach to Managing Heart Failure A Population Health Approach to Managing Heart Failure 259 Prospect Plains Rd, Bldg H, Monroe, NJ 08831 © 2025 MJH Life Sciences® and AJMC®. All rights reserved.